Stockscreener 앱 받기
1.05
0.00%
0.00
전일 마감가:
$1.05
열려 있는:
$1.08
하루 거래량:
553.40K
Relative Volume:
0.84
시가총액:
$133.62M
수익:
순이익/손실:
$-18.43M
주가수익비율:
-6.7394
EPS:
-0.1558
순현금흐름:
$-12.87M
1주 성능:
-11.76%
1개월 성능:
+36.35%
6개월 성능:
-21.64%
1년 성능:
-48.02%
1일 변동 폭
$1.03
$1.10
1주일 범위
$1.02
$1.20
52주 변동 폭
$0.7615
$2.15
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Compare TLSA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.05 | 133.62M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-03 | 개시 | BTIG Research | Buy |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
A rare disorder’s median survival is 6–9 years. Tiziana seeks FDA rare-disease designation for its nasal drug. - Stock Titan
Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com Canada
Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com UK
TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus
Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - Kalkine Media
Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan
A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan
ADAG Stock Price, Quote & News - Syfe
TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance
Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Proactive financial news
Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks
Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus
BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com UK
Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news
Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au
Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors
Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - kommunikasjon.ntb.no
Tiziana Life Sciences Ltd. - Via Ritzau
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 - Yahoo Finance
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - The Manila Times
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tiziana Life Sciences (TLSA) insider adds 42,357 shares via Panetta Partners - Stock Titan
Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy - Stock Titan
Tiziana Life Sciences CEO & Executive Director Acquires 18% More Stock - simplywall.st
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Unprofitable Operations and Low Valuation - GuruFocus
TLSA | Tiziana Life Sciences Ltd. Insider Trading - Quiver Quantitative
Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock - marketbeat.com
Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock - marketbeat.com
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana Life Sciences (Nasdaq: TLSA) CEO boosts stake with 321,423-share buy - Stock Titan
Tiziana Life Sciences announces CEO share purchase - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Purchases 667,000 Shares - MarketBeat
Tiziana Life Sciences (TLSA) CEO buys 667,000 new shares - Stock Titan
Tiziana Life Sciences CEO Boosts Stake as Lead MS Therapy Progresses - The Globe and Mail
Tiziana Life Sciences CEO Boosts Stake as Lead MS Therapy Progresses - TipRanks
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Positive MS T - GuruFocus
Tiziana Life Sciences (NASDAQ: TLSA) CEO purchases 667,000 shares at $1 - Stock Titan
Tiziana CEO adds to holdings - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - manilatimes.net
Tiziana CEO adds to holdings - Proactive financial news
Tiziana Life Sciences (TLSA) Slips 5.8% to $0.97, Approaches Key Support at $0.92Reversal Setup Alerts - dars.gov.et
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tiziana Life Sciences Ltd 주식 (TLSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Elrifi Ivor | Chief Executive Officer |
Aug 04 '26 |
Buy |
0.97 |
83,807 |
81,293 |
4,556,068 |
| Elrifi Ivor | Chief Executive Officer |
Aug 03 '26 |
Buy |
1.00 |
667,000 |
667,000 |
4,472,261 |
4.22%
자본화:
|
볼륨(24시간):